Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash & Current Investments: 2010-2024

Historic Cash & Current Investments for Sunshine Biopharma (SBFM) over the last 12 years, with Dec 2024 value amounting to $9.7 million.

  • Sunshine Biopharma's Cash & Current Investments fell 23.76% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.5 million, marking a year-over-year decrease of 34.73%. This contributed to the annual value of $9.7 million for FY2024, which is 40.55% down from last year.
  • Per Sunshine Biopharma's latest filing, its Cash & Current Investments stood at $9.7 million for FY2024, which was down 40.55% from $16.3 million recorded in FY2023.
  • In the past 5 years, Sunshine Biopharma's Cash & Current Investments registered a high of $21.8 million during FY2022, and its lowest value of $997,478 during FY2020.
  • Over the past 3 years, Sunshine Biopharma's median Cash & Current Investments value was $16.3 million (recorded in 2023), while the average stood at $15.9 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first spiked by 1,974.15% in 2020, then slumped by 40.55% in 2024.
  • Over the past 5 years, Sunshine Biopharma's Cash & Current Investments (Yearly) stood at $997,478 in 2020, then spiked by 105.79% to $2.1 million in 2021, then spiked by 963.27% to $21.8 million in 2022, then declined by 25.35% to $16.3 million in 2023, then tumbled by 40.55% to $9.7 million in 2024.